Join
Live feed
·
INSIDERFilingvia Quantisnow
Akebia Therapeutics Inc. logo

Director Wolf Myles was granted 35,700 shares, increasing direct ownership by 37% to 133,381 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
AKBA· Akebia Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AKBA (Akebia Therapeutics Inc.) and more on Quantisnow.